相关实验视频

Updated: Jan 10, 2026

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

转金属化在癌症药理学中的作用

Mahendiran Dharmasivam¹, Busra Kaya¹

¹Institute for Biomedicine and Glycomics, Griffith University, Southport, QLD 4215, Australia.

International journal of molecular sciences

|November 27, 2025

概括

转金属化使癌症金属药理学能够通过将惰性金属复合物转化为瘤细胞内的活性金属复合物. 这种有针对性的方法局部化了细胞死亡机制,提供了一种新的治疗策略.

科学领域:

金属药理学是指金属药理学.
协调化学协调化学
癌症治疗方法癌症治疗方法

背景情况:

转金属化,即金属离子的交换,是金属制药设计中的一个关键机制.
二甲基 (TSCs) 作为金属复合的多功能连接体.

研究的目的:

在癌症治疗中探索金属药物的条件激活转移.
研究金属离子交换如何影响药物疗效和瘤细胞向.

主要方法:

采用了二氧化甲 (TSCs) 作为传染研究的模型系统.
比较了氧化还原活性和氧化还原惰性金属复合物 (例如,Zn (II),Ga (III),Cu (II),Fe (III/II)).
分析了下游效应,包括ROS生成,铁缺乏和细胞死亡途径 (亡,铁亡).

主要成果:

在酸性瘤溶解体中,已经证明了氧无氧金属复合物 (Zn(II,Ga(III)) 在现场转化为氧活性物种 (Cu(II,Fe(III/II)).
这种条件激活局部反应性氧物种 (ROS) 生产和铁剥夺癌细胞.
发现诸如连接器调整和金属识别等因素决定了交换动力学和有效性.

结论:

转金属化是癌症金属制药学的强大和可通用的治疗原则.
诸如绝缘屏蔽和前期药物设计等策略可以减轻非目标效应并改善临床翻译.
需要进一步的研究来量化细胞内动力学和优化组合疗法.

关键词:

铜/铁的药理学铁性化 (ferroptosis) 是一种溶酶体向性向性向性有活性氧物种的反应性氧物种.这种类型的血性arbazone.传递的变化是传递的.

更多相关视频

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...